Resveratrol plus carboxymethyl-β-glucan in infants with common cold: A randomized double-blind trial

Abstract Objectives To evaluate effectiveness of a nasal resveratrol/carboxymethyl-β-glucan solution compared to nasal saline solution: a) on common cold symptoms by means of a validated measure scale (CARIFS score), b) on Rhinovirus infection and CCL2, CCL5, IL8, IL6, CXCL10 and TLR2 expression in nasal swabs, c) on frequency of relapses after 30 days of follow-up. Methods 89 infants with respiratory infection symptoms were randomly assigned to receive either a nasal resveratrol/carboxymethyl-β-glucan solution or nasal saline solution. All patients were evaluated with CARIFS score at enrollment, after 48 hours, 7 and 30 days by physicians and parents. Nasal swabs were obtained at enrollment, after 48 hours and after one week. Results CARIFS score improved in both groups. Episodes of sneezing and cough were fewer in study group after 7 days of follow-up (p Conclusions These data suggest that a solution containing resveratrol plus carboxymethyl-β-glucan might be have a positive impact on both clinical and socio-economic burden due to infant common cold.